What do the updated prevention and risk screening strategies for breast cancer look like in practice? Here to share how the MD Anderson Cancer Center at Cooper University Health Care has adopted those strategies is Dr. Pallav Mehta.

What do the updated prevention and risk screening strategies for breast cancer look like in practice? Here to share how the MD Anderson Cancer Center at Cooper University Health Care has adopted those strategies is Dr. Pallav Mehta.

What is the role of autoantibodies in breast cancer detection? Dr. Pallav Mehta, the Director of Integrative Oncology and Practice Development at the MD Anderson Cancer Center at Cooper University Health Care, shares the latest research on autoantibodies as potential biomarkers in the early detection of breast cancer.

Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology/Oncology Fellowship at the University of Arizona Cancer Center, discusses the utility of prognostic markers to improve outcomes for patients with breast cancer.

Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology/Oncology Fellowship at the University of Arizona Cancer Center, examines current clinical trials investigating the role of CDK 4/6 inhibitors in early stage HER positive and HER2 negative breast cancer treatment.

Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology/Oncology Fellowship at the University of Arizona Cancer Center, examines current clinical trials investigating the role of CDK 4/6 inhibitors in early stage HER positive and HER2 negative breast cancer treatment.

Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology/Oncology Fellowship at the University of Arizona Cancer Center, discusses the utility of prognostic markers to improve outcomes for patients with breast cancer.

What are some of the most recent advancements in RET diagnostics? Dr. Balazs Halmos discusses molecular testing for patients with non-small cell lung cancer, or NSCLC, and best practices to use when treating patients with RET alterations.

How is multiplex testing with next-generation sequencing different from other diagnostic tools? Dr. Balazs Halmos, the Director of Thoracic Oncology and Clinical Cancer Genomics at Montefiore Medical Park at Eastchester in the Bronx, New York, discusses how this type of testing can contribute to improved health outcomes and tailored treatment regimens for patients with non-small cell lung cancer, or NSCLC.

Often diagnosed in its later stages, lung cancer often leaves little time for treatment. But an preventive screening technique may help detect this disease early on. Andrea Mckee discusses the lung cancer screening guidelines from the U.S. Preventative Services Task Force and what to know about prevention screening using a low dose computed tomography (LDCT) to help close the time gap.